Aprea Therapeutics Q2 net loss $0.53/sh; cash $16.5M; clinical activity in APR-1051 and ATRN-119

Aprea Therapeutics, Inc.

2025-Q2 EPS reported -$1.19 vs consensus -$0.76 ▼ miss (-56.6%)

Cash and cash equivalents $16.5M as of June 30, 2025, down from $22.8M at Dec 31, 2024; runway into Q2 2026.
Q2 2025 operating loss $3.4M vs $3.8M in Q2 2024; net loss $3.2M ($0.53 per share) vs $3.5M ($0.58 per share).
Phase 1 ACESOT-1051 trial of WEE1 inhibitor APR-1051: 3 patients with stable disease at 70mg/100mg; dose escalation to 150mg planned.
Phase 1/2a ABOYA-119 trial of ATRN-119: 7 patients stable disease, 3 with tumor shrinkage (7%-21%) at 550mg BID; now dosing 400mg BID.
Additional safety/efficacy data expected H2 2025; RP2D for ATRN-119 and dose-escalation completion for APR-1051 expected H1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.